Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings
- PMID: 15701884
Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings
Abstract
The recent past has witnessed the appearance of substantial data relating to endocrine therapy of breast cancer. In the adjuvant therapy setting in early breast cancer, several large, well-conducted, randomized, double-blind clinical trials have provided evidence for the value of the third-generation aromatase inhibitors (AI) anastrozole, exemestane, and letrozole. The three major studies to date [i.e., Arimidex, tamoxifen alone, or in combination (ATAC), International Exemestane Study (IES), and letrozole after 5 years of tamoxifen (MA.17)] evaluated three different populations of women from the standpoints of duration of prior tamoxifen and thus time since the treatment of the primary breast cancer. A consistent pattern of improvement in disease-free survival was seen whether the control arm was tamoxifen (ATAC and IES) or placebo following tamoxifen (MA.17). From a toxicity standpoint, the major findings with the AIs were a decreased incidence of thromboembolic events and endometrial cancers but an increase in musculoskeletal complaints and potential for decreasing bone density. The last issue should be clarified with ongoing studies addressing the impact of the three AIs on bone density and fractures. In summary, based on ATAC, IES, and MA.17, respectively, the following conclusions can be drawn relating to postmenopausal women with hormone receptor positive early breast cancer: anastrozole is a reasonable choice for initial endocrine adjuvant therapy, exemestane should be considered for women who have received 2 to 3 years of tamoxifen, and letrozole should be considered for those who have completed about 5 years of tamoxifen. In the prevention setting, tamoxifen has been evaluated in multiple trials involving >28,000 women and, despite clear evidence of benefit, the level of acceptance of this agent by women seems to be low. Two recently developed prevention trials, IBIS 2 and MAP.3, involve the study of aromatase inhibitors against a placebo control rather than tamoxifen. Whereas the recent adjuvant trials have established the value of the third-generation aromatase inhibitors in early-stage breast cancer, the marked reductions in contralateral breast cancers seen in these trials suggest they will be of value in the prevention setting in women at increased risk of developing the disease.
Similar articles
-
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.Clin Ther. 2005 Nov;27(11):1671-84. doi: 10.1016/j.clinthera.2005.11.013. Clin Ther. 2005. PMID: 16368441 Review.
-
Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.Ann N Y Acad Sci. 2009 Feb;1155:141-61. doi: 10.1111/j.1749-6632.2009.03688.x. Ann N Y Acad Sci. 2009. PMID: 19250201 Review.
-
The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.Eur J Cancer. 2005 Aug;41(12):1678-89. doi: 10.1016/j.ejca.2004.10.020. Epub 2004 Nov 25. Eur J Cancer. 2005. PMID: 16098456 Review.
-
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.Curr Med Res Opin. 2006 Aug;22(8):1575-85. doi: 10.1185/030079906X120940. Curr Med Res Opin. 2006. PMID: 16870082 Review.
-
The use of aromatase inhibitors in adjuvant therapy for early breast cancer.Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:32-8. doi: 10.1007/s00280-005-0101-9. Cancer Chemother Pharmacol. 2005. PMID: 16273366 Review.
Cited by 8 articles
-
Modulation of estrogen synthesis and metabolism by phytoestrogens in vitro and the implications for women's health.Toxicol Res (Camb). 2017 Sep 8;6(6):772-794. doi: 10.1039/c7tx00184c. eCollection 2017 Nov 1. Toxicol Res (Camb). 2017. PMID: 30090542 Free PMC article. Review.
-
Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.Cancer Res. 2014 Aug 1;74(15):4099-110. doi: 10.1158/0008-5472.CAN-13-3156. Cancer Res. 2014. PMID: 25062775 Free PMC article.
-
Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients.Clin Cancer Res. 2011 Jun 15;17(12):4177-86. doi: 10.1158/1078-0432.CCR-10-2950. Epub 2011 Apr 1. Clin Cancer Res. 2011. PMID: 21459801 Free PMC article.
-
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.Cancer Res. 2010 Apr 15;70(8):3278-86. doi: 10.1158/0008-5472.CAN-09-3024. Epub 2010 Mar 30. Cancer Res. 2010. PMID: 20354183 Free PMC article.
-
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.Int J Cancer. 2010 Oct 15;127(8):1748-57. doi: 10.1002/ijc.25207. Int J Cancer. 2010. PMID: 20104523 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Full Text Sources
-
Medical
-
Miscellaneous